Harmen Beurmanjer

107 References References Abanades, S., Farré, M., Segura, M., Pichini, S., Pastor, A., Pacifici, R., …Torre, R. D. La. (2007). Disposition of gamma-hy- droxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: Issues in methodology and drug monitoring. Therapeutic Drug Monitoring , 29 (1), 64–70. https://doi.org/10.1097/ FTD.0b013e3180307e5e Addiction, E. M. C. for D. and D. (2019). European Drug Report. In European Union Publications Office . https://doi. org/10.1097/JSM.0b013e31802b4fda Addolorato, G., Caputo, F., Capristo, E., Domenicali, M., Bernardi, M., Janiri, L., …Gasbarrini, G. (2002). Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol and Alcoholism , 37 (5), 504–508. https://doi.org/10.1093/alcalc/37.5.504 Addolorato, Giovanni, Leggio, L., Ferrulli, A., Caputo, F., & Gasbarrini, A. (2009). The therapeutic potential of gam- ma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opinion on Investigational Drugs , 18 (5), 675–686. https://doi.org/10.1517/13543780902905855 Addolorato, Giovanni, Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., …Gasbarrini, G. (2007). Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet , 370 (9603), 1915–1922. https://doi.org/10.1016/ S0140-6736(07)61814-5 Agabio, R., Preti, A., & Gessa, G. L. (2013). Efficacy and tolerability of baclofen in substance use disorders: A systematic review. European Addiction Research , Vol. 19, pp. 325–345. https://doi.org/10.1159/000347055 American Psychiatric Association. & American Psychiatric Association. DSM-5 Task Force. (2013). Diagnostic and statistical manual of mental disorders [Elektronisk resurs]: DSM-5, 5th ed. VA: American Psychiatric Association. Andrews, G., & Peters, L. (1998). The psychometric properties of the Composite International Diagnostic Interview. Social Psychiatry and Psychiatric Epidemiology . https://doi.org/10.1007/s001270050026 Andriamampandry, C., Taleb, O., Kemmel, V., Humbert, J.-P., Aunis, D., & Maitre, M. (2006). Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain. The FASEB Journal , 21 (3), 885–895. https://doi.org/10.1096/fj.06-6509com Arunogiri, S., Moayeri, F., Crossin, R., Killian, J. J., Smith, K., Scott, D., & Lubman, D. I. (2020). Trends in gamma-hydroxy- butyrate-related harms based on ambulance attendances from 2012 to 2018 in Victoria, Australia. Addiction . https://doi.org/10.1111/add.14848 Bay, T., Eghorn, L. F., Klein, A. B., & Wellendorph, P. (2014). GHB receptor targets in the CNS: Focus on high-affinity binding sites. Biochemical Pharmacology , 87 (2), 220–228. https://doi.org/10.1016/j.bcp.2013.10.028 Becker, H. C. (2017). Influence of stress associated with chronic alcohol exposure on drinking. Neuropharmacology . https://doi.org/10.1016/j.neuropharm.2017.04.028 Beraha, E. M., Salemink, E., Goudriaan, A. E., Bakker, A., de Jong, D., Smits, N., …Wiers, R. W. (2016). Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology , 26 (12), 1950–1959. https://doi.org/10.1016/j. euroneuro.2016.10.006 BESSMAN, S. P., & FISHBEIN, W. N. (1963). GAMMA-HYDROXYBUTYRATE, A NORMAL BRAIN METABOLITE. Nature , 200 , 1207–1208. Beurmanjer H, Verbrugge CAG, Schrijen S, S. A., & DeJong CAJ, D. B. (2016). Treatment of patients withGHB dependence. End report of the GHB Monitor 2.0 [ report in Dutch]. Nijmegen: NISPA. Beurmanjer, H, Asperslag, E. M., Oliemeulen, L., Goudriaan, A. E., De Jong, C. A. J., Schellekens, A. S. A., & Dijkstra, B. A. G. (2019). A Qualitative Approach in Understanding Illness Perception and Treatment Needs in Patients with Gamma Hydroxybutyrate Use Disorder. European Addiction Research . https://doi.org/10.1159/000500807 Beurmanjer, Harmen. (2016). GHB afhankelijkheid : ziektepercepties en behandelingsbehoeftes . Beurmanjer, Harmen, Asperslag, E. M., Oliemeulen, L., Goudriaan, A. E., De Jong, C. A. J., Schellekens, A. S. A., & Dijkstra, B. A. G. (2019). A Qualitative Approach in Understanding Illness Perception and Treatment Needs in Patients with Gamma Hydroxybutyrate Use Disorder. European Addiction Research . https://doi.org/10.1159/000500807 Beurmanjer, Harmen, Kamal, R. M., de Jong, C. A. J., Dijkstra, B. A. G., & Schellekens, A. F. A. (2018). Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non- Randomized, Controlled Trial. CNS Drugs , 32 (5), 437–442. https://doi.org/10.1007/s40263-018-0516-6